Athena Athena

X
[{"orgOrder":0,"company":"Delpharm Group","sponsor":"First Wave BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Delpharm Group

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under this agreement, Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients with Cystic Fibrosis.

            Lead Product(s): MS1819

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: First Wave BioPharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement April 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY